Selected Grants
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC)(DeLLphi-309)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 express
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2025 - 2030A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2024 - 2029An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Zai Lab · 2024 - 2029C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by AbelZeta Inc. · 2024 - 2029A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Immuneering Corporation · 2024 - 2028Amgen 20190341
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028GT103_HCRN_NSCLC
Clinical TrialPrincipal Investigator · Awarded by Hoosier Cancer Research Network, Inc · 2023 - 2027Amgen AMG 757 (SCLC)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2027A Phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of ABBV-303, as monotherapy and in combination with budigalimab (ABBV-181), in adult subjects with advanced solid tumors
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2024 - 2027CNS PATTERN: CNS Progression After Targeted Therapy and Effect of Radiation in NSCLC
FellowshipMentor · Awarded by Lung Cancer Initiative of North Carolina · 2025 - 2026Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Clinical TrialPrincipal Investigator · Awarded by Grid Therapeutics LLC · 2020 - 2026A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
Clinical TrialPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2017 - 2025Clinical and Therapeutic Implications of the Small Nucleolar RNA Snord67 in Breast Cancer Lymphatic Metastasis
ResearchMentor · Awarded by American Society of Clinical Oncology · 2024 - 2025A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Array BioPharma Inc · 2019 - 2025Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC
Clinical TrialPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2025Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT).
Clinical TrialPrincipal Investigator · Awarded by Achilles Therapeutics · 2020 - 2025A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2015 - 2025An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)
Clinical TrialPrincipal Investigator · Awarded by Achilles Therapeutics · 2021 - 2025A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2016 - 2025A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Taxane in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2024A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer
Clinical TrialPrincipal Investigator · Awarded by TCR2 Therapeutics Inc. · 2023 - 2024Adaptimmune SURPASS
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2019 - 2024Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated Brain Metastases (HCRN-LUN19-247)
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2024A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2024A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Clinical TrialPrincipal Investigator · Awarded by Spectrum Pharmaceuticals, Inc · 2017 - 2023Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety andTolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participa
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2019 - 2023CBMG NSCLC Tumor Specimens for TIL Cell Therapy
ResearchPrincipal Investigator · Awarded by Cellular Biomedicine Group, Inc. · 2020 - 2023A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2021 - 2023Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2022Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions
ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2022"Understanding the Patient Experience of Stage 3 Unresectable Non-Small Cell Lung Cancer (NSCLC) in the Immuno-oncology Era"
ResearchCo Investigator · Awarded by AstraZeneca PLC · 2020 - 2022AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, EMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB,AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDIC
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2016 - 2022Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) (PACIFIC-4/RTOG-3515)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2020 - 2022Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2020 - 2021A Phase III, Multicenter, Rancomized Open-Label Study Evaluating the Efficacy and Safety of MPD3280A (Anti-PD-L1 Antibody)in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy-Naive Patients with Stage IV NSCLC
Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2015 - 2020A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2020Adaptimmune MAGE A-4
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2018 - 2020Adaptimmune MAGE
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune Limited · 2018 - 2020First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors
Clinical TrialPrincipal Investigator · Awarded by MedPacto, Inc · 2014 - 2020An open-label Phase I dose-escalation study to evaluate the safety, tolerability, max. tolerated dose, pharmacokinetics,and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects w/ advanced solid tumors known to expressC4
Clinical TrialPrincipal Investigator · Awarded by Bayer HealthCare AG · 2017 - 2019A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or GIST.
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2013 - 2019Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer
ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2016 - 2018Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer
FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2015 - 2018A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor Administered with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours
Clinical TrialPrincipal Investigator · Awarded by Eli Lilly and Company · 2016 - 2018Blood-based Biomarker Profiling for TEW-7197
ResearchPrincipal Investigator · Awarded by MedPacto, Inc · 2016 - 2018External Relationships
- AbbVie, Inc.
- Amgen
- Biothera
- Blackdiamond
- Bristol-Myers Squibb (BMS)
- CDR Life
- Coherus
- Cornerstone Specialty Network
- G1 Therapeutics, Inc.
- Merck
- Synthekine
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.